SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, has today provided an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.
Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month.”
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain.
The company platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics plc received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix Health Plc (LON:OPTI).
The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.
